Trouble in the Repo Market

Posted by & filed under Accounting Information Systems, Accounting Principles, Advanced Accounting, All Articles, Auditing, Cost Accounting, Financial Accounting, Income Taxes, Intermediate Accounting, Managerial Accounting, Uncategorized, Video Updates.

According to the Bank for International Settlements, the Financial Times reports that turmoil in the repo market was fueled by hedge funds need to borrow cash in order to drive returns on trades. Questions: What is the Repo market? Why is the pullback by bank lending a bad sign? Explain the increasingly popular hedge fund… Read more »

Ramen Noodles are the new Prison Currency!

Posted by & filed under Accounting Information Systems, Accounting Principles, Advanced Accounting, All Articles, Auditing, Cost Accounting, Ethical Dilemma, Financial Accounting, International Accounting, Managerial Accounting.

At some state prisons, budget cuts have led to a reduction in the caliber and total number of meals that prisoners receive, which means that the practical value of ramen noodles have skyrocketed in their value as contra ban. Questions: 1. According to the article, why don’t prisoners stock up on Ramen, since it commands… Read more »

Walmart vs. Amazon: A Grocery War?

Posted by & filed under Accounting Information Systems, Accounting Principles, Advanced Accounting, All Articles, Auditing, Cost Accounting, Financial Accounting, Intermediate Accounting, Managerial Accounting, Video Updates.

Questions: 1. Do you see this as a competition between Walmart and Amazon? Why or why not and are there any other players in the grocery war? 2. According to the video, why didn’t Walmart just create their own logistical team rather than use Uber and Lyft? 3. Would you be willing to pay $7… Read more »

A Big Bet!

Posted by & filed under Accounting Information Systems, Accounting Principles, Auditing, Cost Accounting, Financial Accounting, Intermediate Accounting, Managerial Accounting.

Pfizer is making a $15.2 billion bet on the drug industry‚Äôs new, more elite class of generics, which are costly, complex copies of already expensive biotech drugs. Questions: 1. What are biosimilars? 2. Why are there questions about the durability of the market for these specialty drugs? 3. What is the dollar estimate of the… Read more »